Ex-Novartis consumer vet takes Glaxo JV reins from CEO-bound Walmsley

gskhq

GlaxoSmithKline CEO-to-be Emma Walmsley will leave a chair vacant at the top of its key consumer health JV, and stepping in to take it is Brian McNamara, a Novartis exec who joined the venture with last year's asset swap.

McNamara, now GSK Consumer Healthcare’s Europe and Americas chief, is stepping in to fill Walmsley's spot, effective immediately, the company said Thursday. He’ll report to current head honcho Andrew Witty until Walmsley takes the reins next March.

McNamara joined GSK last year when GSK and Novartis tied up on the Glaxo-controlled consumer health JV, part of the multibillion-dollar asset swap between the two pharma giants. McNamara has plenty of previous consumer goods experience; he spent 11 years at Novartis in consumer roles, and before that, 16 years at Procter & Gamble.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Witty said that McNamara's experience makes him “the clear choice to build on the current momentum we are seeing in our business." Working with consumer brands for years will help him "fully maximize" GSK's product lines to "deliver the benefits" of the GSK-Novartis combo, the CEO explained.

Building on current momentum has been a theme for Glaxo as it edits its executive ranks. Witty’s much-maligned strategy--to pump high volume through the traditionally low-margin businesses of consumer health and vaccines, while exiting pharma spaces where pricing pressure can play spoiler to sales--is just starting to pay off, and the company’s insider CEO pick signaled to investors that Glaxo wants to see his vision through.

Some investors still want things their way, though, and as head of consumer, McNamara will be right in the middle of the controversy. Prominent shareholder Neil Woodford began lobbying for a large-scale company breakup--starting with a consumer health spinoff--late last year, and that idea gained plenty of traction before Witty shut it down in February.

"Time is everybody's friend" when it comes to getting the OTC business and its operating margin up to where it should be, at 20% or higher, Witty explained--a journey he anticipates taking three years.

"I think sometimes people think, 'oh, let's just put together these two massive companies … on Monday, and on Tuesday, let's do something completely different with them,'" he said at the time. And while he ceded that it would be "disingenuous" not to acknowledge that the unit's newfound scale could make divesting it an option down the road, "if I had to make that call today, I'd stick to what we have," he said.

Meanwhile, the consumer unit won't be the only division with a new leader when next year rolls around. Back in June, the British drugmaker announced that vaccines chief Moncef Slaoui would follow Witty out the door, capping a nearly 30-year run at the company.

Related Articles:
Should change-minded GSK investors be grumbling about its insider CEO pick?
GSK replaces Witty with consumer chief Emma Walmsley, Big Pharma's first woman CEO
With strong Q2, GSK chief Witty sees solid growth platform for his replacement
More exec turnover at GSK: Vax chief Slaoui to follow CEO Witty out the door next year
Hold your horses on an OTC spinoff, GSK chief tells breakup-happy analysts
GSK chief Witty may be leaving, but he hopes his strategy sticks around

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.